Wednesday, November 30, 2016

Drug limited type to kill cancer cells with DNA repair defects could treat leukemia

Tags
Drug limited type to kill cancer cells with DNA repair defects could treat leukemia -

A team of scientists led by Associate Research Professor Motomi Osato and Professor Yoshiaki Ito science cancer Institute of Singapore (Singapore CSI) at the national University of Singapore (NUS) found that a drug originally designed to kill a limited type of cancer cells with DNA repair defects could be used to treat leukemia and other cancers.

The new study suggests that treatment with poly (ADP-ribose) polymerase (PARP) inhibitors and standard chemotherapy drugs might be more effective in the fight against leukemia. In the same study, the researchers found that inactivation of genes RunX cause DNA repair defects and promotes the development of leukemia and other cancers. The study was published online in the leading journal Cell Reports last month.

Unlike other cancers that are most commonly seen in the elderly, leukemia is known for its high prevalence among young people. There has been little progress in the treatment of leukemia. Chemotherapy with or without transplantation of hematopoietic stem cells remains the current standard of care, resulting in a rate of about 50 percent recovery. The genes of the RUNX family are among the most commonly inactivated genes in leukemia and other cancers. Previous studies, RUNX1 is one of the most frequently mutated genes in leukemia and RUNX3 is involved in the development of the disease.

In this study, the research team also showed the link between genes RunX family and the path of human rare congenital disease called Fanconi anemia for the first time. The disease is caused by mutations in one of the 15 genes responsible for repair of a specific type of DNA damage. In the early stages of this study, the researchers found that deficiency RUNX resulted in an inability to produce blood cells and a massive expansion of abnormal hematopoietic cells. They recognized that these clinical manifestations are symptoms of Fanconi anemia and began to investigate the functions of RunX in this DNA repair pathway.

Other research has shown that RunX proteins play an essential and central role in the way of Fanconi anemia by facilitating the recruitment of a protein involved in the repair of DNA damage called FANCD2 to DNA damage sites. This unknown relationship between RUNX and Fanconi anemia prompted the research team to test the possibility that PARP inhibitors, a drug originally designed to kill a limited type of cancer cells to repair defects DNA, could be applied in the treatment of leukemia and cancers with RUNX alterations. These types of cancer were previously not thought to have DNA repair defects. Researchers have shown that the drug was effective in the treatment of leukemia and other cancers in cell culture experiments.

Dr. Osato said, "Common sense is often a veil that prevents us from understanding the truth. PARP inhibitors have been with us for some time, but nobody has made their application for leukemia. Our study has highlighted the possibility of more effective treatment using combination therapy with PARP inhibitors that can potentially be extended to other types of common cancers. "

A new study aims to measure the behaviors, attitudes of smokers who use both cigarettes and e-cigarettes

Tags
A new study aims to measure the behaviors, attitudes of smokers who use both cigarettes and e-cigarettes -

The use of electronic cigarettes ( "e -Cigarettes ") has increased dramatically in recent years. The majority of new "vapers" already were cigarette smokers. To date, little is known about how the e-cigarette use changes over time or how it affects the use of traditional cigarettes. Such information would be useful in understanding the long-term impact of e-cigarettes and whether e-cigarettes help or hurt quitting.

The National Institutes of Health has awarded Moffitt Cancer Center Research Grant to study changes in the cigarette and e-cigarette traditional use over time among people who currently use both products. EASE Project (E-cigarette smoking and evaluation) is a national study that will follow 2,500 participants for two years to measure their behaviors and attitudes toward cigarettes and e-cigarettes. Participants will conduct brief surveys at intervals of three months.

"Electronic cigarettes have already changed the world of nicotine and tobacco, as well as research is still catching up," said Thomas H. Brandon, Ph.D., chair of the Department of results health and behavior and director of the tobacco research and Intervention Program at Moffitt. "therefore, most of the advice offered on the topic of vaping is based on opinion and conjecture rather than evidence. This study is designed to provide public health and medical communities with the data they need to give the best advice to smokers and vapers. "

people who smoke and vape who are interested in learning about participation in the study nationwide ProjectEASE.Moffitt.org can visit or call 1-877-954-2548.

Tuesday, November 29, 2016

Scientists pave the way for better tools to diagnose, predict and control the cancer

Tags
Scientists pave the way for better tools to diagnose, predict and control the cancer -

Scientists have shown how to better identify and measure vital molecules that control the behavior cell - opening the way to improved diagnostic tools, forecasting and monitoring of cancer

Research UK researchers at Manchester cancer Institute based at the University of Manchester -. Part Cancer Research Centre Manchester - and the Institute for Research on Cancer, London, looked at protein kinases, molecules that control various aspects of cellular function.

The study, funded by a Biotechnology and Biological Sciences Research Council (BBSRC) / Pfizer CASE studentship and CRUK, was published in Nature Methods this week (24 August).

previous work has shown that mutations or increases in a range of protein kinases are associated with tumor growth, and for several decades, researchers have sought to develop drugs that target and prevent this activity in order to kill cancer cells. Ten types of drugs that reduce the activity have so far been approved for the treatment of cancer patients.

Dr Claus J-rgensen, which carried out the study as a team leader in the Division of Cancer Biology at research institute on cancer, London, before taking a new position as head of the group of oncology Systems Institute at Manchester Cancer Research UK, said: "protein kinases regulate how cells communicate When these molecules are deregulated, it corresponds to cells" hearing voices "with. a result change in their behavior. Doctors need a way to track changes in kinase levels in individual tumors so they can see how they respond to treatment and match patients to the treatment that works best for them. "

the team studied the make-up of over 0 protein kinases. They used a technology called mass spectrometry to develop a method to both identify and measure the amount of various kinases in a biological sample -. for example from a portion of a tumor removed in surgery

"Our new method can correctly measure the amount of protein kinases in a sample. This means that we can monitor the behavior of cancer cells and also how tumors respond differently to therapy in cancer patients, "added Dr. J-rgensen.

MtDNA mutant Selfish operates cellular defenses to cause many diseases

Tags
MtDNA mutant Selfish operates cellular defenses to cause many diseases -

Mitochondrial disorders are a group of diseases that take many different forms and vary greatly from person to chameleon .

mitochondria are present in specific organelles of cells which produce most of the chemical energy that powers cellular operations. mitochondrial dysfunction has been associated with a wide variety of diseases, including autism, Alzheimer's disease, schizophrenia, dementia, Parkinson's disease, epilepsy, stroke, cancer, fatigue syndrome and chronic cardiovascular diseases.

There are a number of different factors that can cause mitochondria to misbehave. However, mutations in mitochondrial DNA (mtDNA) are known to play a disproportionate role. Now a team of researchers from Vanderbilt University found that the mutant mtDNA can cause diseases by acting "selfishly." - In a way that is beneficial them while harming their host

The Vanderbilt researchers identified the specific molecular mechanisms selfish use of mutant mtDNA to bypass molecular control mechanisms that cells have developed to regulate mitochondrial activity. Detailed understanding of these molecular pathways could help researchers to develop effective treatments for mitochondrial diseases.

Prevalence mitochondrial disorders

"About a newborn on 0 inherits a potentially pathological mitochondrial disease that occurs in about one adult in 5000," said the assistant professor of science biological Maulik Patel, who led the Vanderbilt researchers. Their work is described in the "dynamic homeostatic responses regulate selfish mitochondrial genome of C. elegans," published in the July 12 issue of the journal Cell Metabolism.

team members who contributed to the study were Vanderbilt PhD and Bryan Gitschlag Cait Kirby and associate professor of molecular physiology and biophysics David Samuels, Senior Research Specialist and Gangula Rama and Simon Mallal Major EB Shulman, professor of infectious diseases and inflammation at Vanderbilt school of Medicine.

"Once we know the mechanisms that mutant mitochondria use to escape the cell regulation, then we can develop drugs that target these pathways and prevent the spread of mutations," said Patel.

mitochondria are a unique feature in eukaryotic cells, the cell types found in plants and animals. The generally accepted theory is that mitochondria were originally independent bacteria that have developed an ability to use highly toxic oxygen molecules as a source of powerful energy: a capacity that prokaryotic cells lacking. So some prokaryotes have found ways to convert the mitochondria in a "endosymbiont," an organism that lives in the body of another organism. According to a popular theory, this symbiosis was so successful that it has provided eukaryotes with the added energy they need to start forming multicellular organisms.

Powerhouse of the cell

Although self contained mitochondria are generally known by their role as "the power of the cell," they are also involved in a number of other cellular activities, including cell cycle regulation and cell growth

one of the things that are. single mitochondria is that they have managed to maintain their own DNA through the process of endosymbiosis. the mitochondrial genome is extremely small compared to the massive human genome and consists of a closed ring of 37 genes inherited only from the mother.

the number of copies of mitochondrial DNA in human cells differs widely depending on the type of cell. for example, human blood cells do not carry at all as human liver cells can harbor more thousands of copies each.

in a normal cell, all copies of mtDNA is the same. However, cells contain molecular mechanisms dismantle and destroy components of unnecessary or malfunctioning cells, including the mitochondria. Consequently, these organelles may be reproduced and destroyed at a very high pace. In the resulting mixture, mutant mtDNA can occur. If they reach high levels they become pathogenic.

unusual properties of mitochondrial diseases

mitochondrial disorders have unusual properties. "Unlike bacterial infections that tend to be all or nothing, mitochondrial infections can range from zero to 100 percent," said Patel. "This makes multi-symptomatic mitochondrial disorders, with many individual differences. A person with a mutant load of 50 percent could be symptom free while another person with 80 percent may have severe symptoms. "In addition, mitochondrial diseases are passed from mother to child, except for developmental disorders, tend to develop later in life.

Patel and his colleagues studied the nature of mitochondrial diseases in the transparent roundworm Caenorhabditis elegans (C. elegans for short), a model animal widely used to explore the basic processes in the development and behavior of multicellular organisms, including humans.

How mutant mtDNA escape of a cell mechanism control regulation

researchers found that cells activate two specific responses to treat mitochondrial dysfunction resulting due to the presence of mutant mtDNA. Paradoxically, however, these same responses allow inadvertently mutant mtDNA from spreading further and proliferate. "In this perspective, the mutant mtDNA can be considered selfish entities that operate regulatory control mechanisms of cells for their own evolutionary interests," said Patel.

mitochondrial genome copy number

the cells have a way to count the number of normal mitochondrial genomes they have. This allows them to make more mitochondrial genomes when they need more energy. the researchers found evidence supporting the prediction co-author Samuels some mutant mitochondrial genomes are invisible to the counting of the machinery of the cell. as a result, cells make more copies of the mutant genomes in a futile quest to achieve optimum energy levels. the end result is harmful over-production of mutant copies.

mitochondrial unfolded protein response

the cells continuously monitor the health status of their mitochondria. When they detect mitochondrial dysfunction, cells try to repair the problem with a procedure called the response of the mitochondrial protein unfolded. In addition to relieving the dysfunction in the mitochondria, the procedure protects against destruction by the cell disassembly mechanisms. Researchers have found evidence that some mutant mitochondria can activate this response, which causes the cell to tolerate their presence and allows the mutant mtDNA to proliferate.

"These are the two cases where the mutant mitochondrial genomes operate cellular defenses for their own interests" selfish "," said Patel.

Monday, November 28, 2016

Isis Pharmaceuticals ISIS-APOCIIIRx begins phase 3 study in CFS patients

Tags
Isis Pharmaceuticals ISIS-APOCIIIRx begins phase 3 study in CFS patients -

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 3 evaluating ISIS-ApoCIII Rx in patients of family chylomicronemia syndrome (FCS). FCS is a rare orphan disease characterized by extremely high levels of triglycerides, which affects about 3,000 to 5,000 patients worldwide. The phase 3 study of ISIS-ApoCIII Rx is a double-blind, placebo-controlled, randomized study of six months in 50 patients diagnosed with FCS. The study will evaluate the efficacy and safety of a 300 mg once weekly doses of ISIS-ApoCIII Rx . The primary endpoint of the study was the percent change in fasting triglycerides from baseline after three months of treatment.

"FCS is a rare and serious genetic disease that is often associated with higher triglyceride levels to 00 mg / dL. Because of their extremely high triglyceride levels, CFS patients are at significant risk many serious health problems, including frequent bouts of pancreatitis, which may require hospitalization and may be life threatening. current treatment options do not reduce enough to reduce the risk of serious illness triglycerides in patients with FCS, "said Sotirios Tsimikas, MD, professor of medicine and director of vascular medicine at the University of California, San Diego and Vice President of clinical development and Chief cardiovascular franchise Isis. "ISIS-ApoCIII Rx provides a unique therapeutic approach in that it is designed to reduce triglyceride levels by reducing apoC-III, an important regulator of the clearance of triglycerides. Data from Phase 2 strongly support advancing ISIS-ApoCIII Rx in phase 3 studies in patients with highly elevated triglycerides as FCS. "

in a phase 2 study, patients treated with FCS ISIS-ApoCIII Rx experienced decreases in triglyceride up to more than 1500 mg / dl. Isis also evaluated ISIS-ApoCIII Rx in a broad Phase 2 program in these studies in patients with triglyceride levels to extremely high very high, patients treated with ISIS-ApoCIII Rx achieved substantial reduction in triglycerides (average percentage reductions of up to 71%) and APOC-III (mean of the percentage discounts up to 88%) and increased HDL cholesterol ( the average percentage increases of up to 78%).

"Our goal is to bring ISIS-ApoCIII Rx on the market for patients with severely elevated triglycerides. These patients are at increased health risk because they can not reduce their triglycerides to safe levels with currently available drugs. We are pleased with the data from our Phase 2 program, in which the triglyceride substantial decrease was achieved when ISIS-ApoCIII Rx was administered as monotherapy or in combination with fibrates in patients with a wide range of incoming triglycerides, including CFS patients, "said Richard Geary, Ph.D., senior Vice President of development at Isis." Our extensive experience in the development of drugs to treat lipid disorders, including good working relationships we have established with physicians and centers that treat many patients FCS should support the rapid progress of this program. We currently expect advance ISIS-ApoCIII Rx without seeking a partner. "

ISIS-ApoCIII Rx is designed to target apoC-III, a protein produced in the liver which plays a central role in the regulation of serum triglycerides. ApoC-III is a genetically validated target for lowering triglycerides. Independent studies have shown a link between the lower activity apoC-III, which results in reduced levels of triglycerides and cardiovascular disease.

In addition to developing ISIS-ApoCIII Rx for patients with FCS, Isis also developing ISIS-ApoCIII Rx for patients with highly elevated triglycerides, higher to 880 mg / dL, a condition that affects about 50,000 patients in the United States and Europe. These patients not only have a high risk of pancreatitis, but also have a higher risk of type 2 diabetes and cardiovascular disease. Current treatments do not sufficiently reduce triglyceride levels in many of these patients to reduce these health risks. Isis plans to launch the Phase 3 program in patients with highly elevated triglycerides in 2014.

Moffitt researchers receive grant to examine cancer metastasis of prostate

Tags
Moffitt researchers receive grant to examine cancer metastasis of prostate -

Moffitt researchers David Basanta, PhD, and Conor Lynch, Ph.D., received a grant of U01 to study prostate cancer metastasis. Prostate cancer often spreads to the bone, and can cause painful bone lesions and increased mortality for patients. Their study will integrate molecular information, cellular and clinical in mathematical models to better understand the key factors driving the disease to help target when metastasis can occur and identify new therapeutic targets for prevention.

Sunday, November 27, 2016

Study: One in every 0 Ontarians diagnosed with inflammatory disease of the intestine

Tags
Study: One in every 0 Ontarians diagnosed with inflammatory disease of the intestine -

One in every 0 Ontarians was diagnosed with inflammatory bowel disease (IBD ), with the number of people living with the disease increased by 64 percent between 1999 and 08, according to a study by researchers at the Institute for Clinical Evaluative Sciences (ICES), East children's Hospital of Ontario (CHEO) and the research Institute Ottawa Hospital. This puts Ontario in the 0th percentile for IBD prevalence worldwide

The study, published this week in Inflammatory Bowel Diseases , is the first and most important Canadian study of IBD -. Including Crohn's disease and ulcerative colitis ─ to demonstrate the incidence trends over time, and the first to review the rates of IBD in the different age groups.

"the number of new diagnoses each year increased from 2.444 in 1999 to 3.342 in 08. This means that the standardized incidence has increased an average of nearly two and a half percent a year since the 0, "said Dr. Eric Benchimol, associate researcher at ICES, and pediatric gastroenterologist at CHEO.

The study population based on all Ontario residents living with IBD from 1999-08 found:

  • There were more than 68,000 residents with Ontario IBD living in the province in 08.
  • the number of new cases of IBD have increased significantly in children under 18 and adults 18 to 64 years
  • the number of new cases of IBD is stable in patients aged over 65 years. However, the prevalence (the number of people living with IBD) increased the most during the study period in patients older than 65 years
  • The elderly population with IBD represents the most dynamic group living with IBD.
  • group with the number of new cases the strongest growth are children under 10 years.

"This important study confirms, once again, that Canadians have more reasons to be concerned about Crohn's disease and ulcerative colitis than anyone in the world," said David Lindee, CEO of Crohn's and ulcerative colitis Canada. "These are the" Canadian disease ", which place a heavy burden on families and the health system in Canada. The work of Dr. Benchimol provides further evidence that we must continue our fight to cure Crohn's disease and colitis improve the lives of children and adults living with these chronic diseases. "

According to the 2012 impact report of IBD Crohn's and ulcerative colitis Canada, IBD cost the Canadian health care system approximately $ 2.8 $ billion in 2012, over $ 11.00 per person with IBD every year.

exposure of the environment and changing demographic trends were reported as possible causes of the disease earlier appearance. For example, the increase in antibiotic utilization, cesarean birth, changes in diet, or using other drugs, all may have led to changes in the microbiome of Ontario's children and soon appearance of the disease.

"The peak number of new cases of IBD is still young adults who are 20 to 40 years of age, but the fastest growing incidence is in children under 10 followed by those 10 to 19 years of age. This may be due to the early onset of the disease, or improved recognition and earlier diagnosis, "said Benchimol.

OVC research may help improve the treatment of cancer

Tags
OVC research may help improve the treatment of cancer -

Cancer treatment in people could be transformed through a study on the treatment of cancer in animals conducted by researchers at the Ontario Veterinary College (OVC) at the University of Guelph.

The results in mice and pets such as cats already lead to clinical trials to treat people with various forms of cancer.

researchers found that injection of oncolytic viruses (viruses that target cancer cells) intravenously in the spleen helps the immune responses to be stimulated much faster and at much higher amplitudes than traditional vaccination methods. Typically, physicians must wait weeks or months to administer a booster shot, in time to stop potentially fatal.

"Normally you have to wait until the immune response is down to administer the booster shot, but it means that serious and dangerous diseases, the answer would decline," said the professor of pathobiology Byram Bridle, lead author of the paper.

"You do not want to give any time the cancer to spread. What is the injection of virus in the spleen is that it allows us to bypass the regulatory mechanism that would limit its effectiveness. When we conducted these tests in animals, we saw the high success rate in the treatment of cancer. "

he said that the findings apply to many types of cancer, including breast cancer , leukemia, prostate cancer and osteosarcoma (bone cancer), and tumors in the brain, liver and skin.

researchers at Guelph and McMaster University have conducted tests in mice, and in cats brought to the animal Cancer Center OVC. the tests on dogs should begin next year.

in traditional treatment options, tumors grew and mice died. When researchers began injecting the virus in the spleen, tumors disappeared.

"by getting the vaccine at this unique place in the body, we were able to get an answer unprecedented immune in a minimum of time, "said Bridle.

"This is a fundamentally new way to treat cancer bypassing many common side effects. These therapies are safer and more focused."

The results have led to clinical trials for people in Ottawa, Hamilton and Toronto.

Bridle said the study could help researchers in other fields, including those seeking to treat virulent diseases such as dengue fever and Ebola.

"My research focuses on cancer, but certainly these results are applicable to other diseases. We just need to connect with people in these areas, "he said.

he is optimistic that human trials will help to improve the treatment of cancer.

" We live in a world where diseases seem to grow faster than treatment, so we need to overcome them. time is of the essence. It is a race that we must win. "

Saturday, November 26, 2016

New discovery of stem cells may lead to a simplified procedure for tissue regeneration

Tags
New discovery of stem cells may lead to a simplified procedure for tissue regeneration -

A new discovery of stem cells could one day lead to a simplified process for obtaining stem cells, which in turn could be used in the development of replacement tissues for not body parts, scientists UC San Francisco who reported the results in the current issue of cell.

work is based on a strategy that involves the reprogramming of adult cells back to an embryonic state in which they once again the potential to become any type of cell.

the efficiency of this process may soon rise through the identification of the biochemical pathways that scientists can inhibit the necessary reprogramming gene activity in adult human cells. Removing these barriers has increased the efficiency of the production of stem cells, the researchers found.

"Our new work has important implications for both regenerative medicine and cancer research," said Miguel Ramalho-Santos, PhD, associate professor of obstetrics, gynecology and reproductive sciences and member the Eli and Edythe Broad Center of regeneration medicine and stem cell research at UCSF, who led the research, funded in part by New Innovator Award prestigious NIH Director.

as soon as it was discovered possible to make specialized cells for adults and reverse the development clock to strip the mature cells of their distinct identities and characteristics - and make them immortal, reprogrammable cells that can theoretically be used to replace any tissue - led to a share of the Nobel in physiology or medicine prize being awarded to UCSF Gladstone Institutes and researcher at Kyoto University Shinya Yamanaka, MD, in 2012.

These induced pluripotent stem (iPS) are considered approach experimental alternative continuous efforts to develop tissue from stem cells derived from early human embryos. However, despite the promise of iPS cells and excitement surrounding research on iPS, the percentage of adult cells successfully converted to iPS cells is generally low, and the resulting cells often retain traces of their lives earlier than specialized cells.

Researchers generate stem cells by forcing the activation in cells pluripotency genes inducing adults - starting with the so-called "Yamanaka factors." - a process that goes back in time on cell maturation

Yet as Ramalho-Santos notes, "from the moment of the discovery of iPS cells, it was appreciated that the specialized cells from which they are derivatives are not a blank slate. they express their own genes that can resist against or reprogramming. "

But the nature of what exactly is getting in the way of reprogramming remained misunderstood. "Now, removing genetically multiple barriers to reprogramming, we found that the production efficiency of iPS cells can be significantly increased," he said. The discovery will help accelerate the safe and effective use of iPS cells and other cells reprogrammed, according to Ramalho-Santos.

The researchers found not just single genes acting as obstacles, but rather sets of genes acting together through different mechanisms to build dams for reprogramming. "At virtually every level of the functions of a cell, there are genes that act in a coordinated way to antagonize closely reprogramming," says Ramalho-Santos. These mechanisms may help adult cells retain their functional roles and identities.

"Like the Red Queen constantly running to stay in the same place in Lewis Carroll's" Through the Looking-Glass, "adult cells seem to put a lot of effort to stay in the same state," at -he said.

to discover this vibrant biochemical matrix not previously identified the activity of inhibitory genes, the scientists had to simultaneously manage several different technical prowess in the laboratory. They combined genetic technologies, cellular and advanced bioinformatics to globally identify genes that act as barriers to the generation of human iPS cells, and probed how these new barriers work.

in addition to maintaining the integrity of our adult tissues barrier genes probably serve important roles in other diseases -. including in the prevention of certain cancers, according to Ramalho-Santos

Changes to the RUNX3 protein may promote the progression of cancer

Tags
Changes to the RUNX3 protein may promote the progression of cancer -

New study also identified a potential way to increase the effectiveness of therapy cancer

scientists at the Singapore science cancer Institute (CSI Singapore) at the national University of Singapore (NUS) found that changes in a protein called RUNX3 can promote progress cancer. The results of the study were published in the prestigious journal of the National Instruments Academy of Sciences (PNAS) in June 2016.

The research team, led by Professor Yoshiaki Ito, senior principal researcher CSI in Singapore, found that phosphorylation of the modification called made RUNX3 promotes the progression of cancer by allowing cell division. uncontrolled cell division in the body is a process by which tumors form and is therefore a characteristic of cancer. RUNX3 is a tumor suppressor gene that prevents the formation of tumors by binding to DNA.

The phosphorylation or addition of a phosphate group to a molecule, is carried out by an enzyme called Aurora kinase, which was observed to be present at abnormally high levels of certain cancers. Phosphorylation prevents RUNX3 of DNA binding, which RUNX3 move to centrosomes, organelles that control the beginning of cell division.

"This study identifies a new post-translational modification in RUNX3, which provides RUNX3 with a novel role in regulating cell division. Our results suggest that frequent overexpression of Aurora kinase in cancer can reduce the RUNX3 transcription activity, leading to cell division and tumor formation. understanding the molecular mechanisms underlying Aurora kinase overexpressing tumors will help in the design of the targeted cancer therapy and personalized, "said Dr. Linda Chuang, senior research scientist at the CSI Singapore, who is the first author of the study.

"Unlike other changes arising from changes in the DNA itself or RUNX3 how DNA is read, phosphorylation not accompanied by changes in DNA and is therefore undetectable level genetics. Since modifications such as phosphorylation may be impermanent and reversible, the clinical implications are far reaching. Moving forward, the team is looking at ways to assess the feasibility of improving RUNX the removal of the tumor or the inhibition of the mitotic RUNX function to quickly kill the proliferation of cancer cells, "said Professor Ito.

Friday, November 25, 2016

First line sunitinib in metastatic RCC top everolimus

Tags
First line sunitinib in metastatic RCC top everolimus
-

By Lynda Williams, Senior medwireNews Reporter

Results for the RECORD-3 trial support, strategy current first-line sunitinib followed by second line of everolimus for the treatment of patients with metastatic renal cell carcinoma (mRCC).

As explained in Journal of Clinical Oncology , the phase II study researchers have hypothesized that the first line everolimus sunitinib followed by the second line at the first sign of disease progression would be better tolerated than the opposite and would therefore offer patients a better progression-free survival (PFS).

However, the median PFS in early second-line treatment was significantly lower for the 238 patients who were randomly assigned to receive primary everolimus for the 233 patients who received first-line sunitinib, 7.9 against 10.7 months with a hazard ratio (HR) of 1.4

the HR exceeds the preset value of 1.1 for the primary endpoint. the upper limit of the range of a side confidence 0% was 1.64, beyond the predefined margin of 1.27.

Thus, the study did not demonstrate non-inferiority to everolimus first line from the first line sunitinib, say Robert Motzer, of Memorial Sloan Kettering Cancer Center in New York, USA and co-authors.

"These clinically relevant differences support the standard processing sequence, so that patients suffering from progression (or intolerant) first-line sunitinib are then treated with everolimus" they write .

Overall, 45% of patients who received everolimus first line switched to a second-line treatment, and 43% of those given in first line sunitinib.

The combined median PFS was 21.1 months for patients who received everolimus and sunitinib first line second line compared to 25.8 months for the first-line sunitinib followed by the second line everolimus; the difference was not significant.

The median overall survival was 22.4 months for the first line and second line everolimus and sunitinib 32.0 months for the first-line sunitinib and everolimus second line, and once again the difference between the arm treatment reached statistical significance.

patients in the everolimus first line and first-line sunitinib group reported similar side effects with stomatitis (53 and 57%), fatigue (45 and 51%) and diarrhea ( 38 and 57%), the most common.

"observes [adverse events] were consistent with the known safety profile of everolimus and sunitinib and differentiated by mTOR [mammalian target of rapamycin] respective inhibitor and VEGFR [vascular endothelial growth factor receptor] tyrosine kinase inhibitor class," Motzer and the team observed

They conclude: ".. the test results support the standard treatment paradigm frontline sunitinib followed by everolimus progression"

licensed medwireNews of Springer Healthcare Ltd. with permission © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.

Nuffield Health improves breast screening service MAMMOMAT Inspiration systems with Siemens Healthineers

Tags
Nuffield Health improves breast screening service MAMMOMAT Inspiration systems with Siemens Healthineers -

largest nonprofit UK Nuffield Health Supplier Health Care as part of its broader investment program improved its breast screening service at a refresh technology that includes six systems of Siemens Healthineers. mammography MAMMOMAT Inspiration systems are in action in a series of Nuffield Health sites, including Woking, Derby, Leicester, Oxford, Cardiff and Hereford. Research shows that one life is saved for every 0 women who are screened * Nuffield Health puts strong emphasis on making it an experience that women feel comfortable to reduce anxiety and encourage the appointment absorption.

Nuffield Health Improves breast screening service for women in the UK. [Left to right] Sue Oliver, professional chef for mammography at Nuffield Health; Lisa Hind, team leader and receptionist; Julie Little, lead nurse in oncology; Alison Bain, Matron; Sue Mozley, radiology assistant manager; Glenda Bwema, Radiology and Director Agness Tembo; Mammographer Derby Hospital Health Nuffield

Sue Oliver, professional chef for mammography and laser safety reviews health Nuffield:

Go to a screening test breast can be a daunting experience. The patient is at the heart of everything we do so we strive to do as much as possible a comfortable experience. The MAMMOMAT Inspiration had a significant impact on how we select patients that the design ensures maximum patient comfort. Some hospitals Nuffield Health have also opted for mood lighting on systems, which helped patients relax during the appointment and put their mind at ease.

The MAMMOMAT Inspiration systems have Opdose ® technology that automatically selects the best combination anode / filter as possible and the optimal dose for the individual characteristics of the breast. The Nuffield Health Hospitals also received workflow efficiency after switching from analog to digital, with a quick turnaround time between patients due to the acquisition of snapshot. The systems are ready Breast true 3D tomosynthesis, the widest angle of 50 ° industry for improved diagnostic capabilities that significantly improves the early detection rate of breast cancer

Glenda Bwema Hospital radiology manager at Derby Hospital Health Nuffield adds .:

the primary advantage of MAMMOMAT Inspiration for the staff at Nuffield Health is that images can be seen immediately, helping to streamline workflow and improve patient throughput. Our Consultant Radiologists find the picture quality is fantastic and adapted to their requirementsThe staff commented on the ease of use and how compression paddles are easy to install, which was helpful when we have an influx of patients.

Vince Golledge, director of corporate sales at Siemens Healthineers comments:

screening is essential for identifying early stages of breast cancer, which, if taken early is easier to treat. According to Cancer Research, the projections in reducing the number of deaths from breast cancer by about 1,300 per year in the UK. Nuffield Health is dedicated to providing the best breast screening service to its patients and MAMMOMAT Inspiration systems help to facilitate this by producing high quality images in a comfortable environment for the patient.

Healthineers Siemens is one of the largest global providers of technology for the healthcare industry and a leader in medical imaging, laboratory diagnostics and healthcare IT. All backed by a comprehensive portfolio of clinical consultation services, training, and services available in the world and tailored to customer needs.

Thursday, November 24, 2016

Feist-Weiller, Caris Life Sciences partner to provide advanced technology to cancer patients

Tags
Feist-Weiller, Caris Life Sciences partner to provide advanced technology to cancer patients -

Doctors Cancer Center LSU Health Shreveport Feist-Weiller will now have access to innovative precision Medicine the technology that determines the unique biological characteristics of the cancerous tumor of each individual patient. Once the information is known, doctors can identify chemotherapy or radiation therapy regimens tailored to attack. The new capacity is the result of the emerging technology known as tumor profiling. Feist-Weiller work with Caris Life Sciences to provide advanced technology to patients with cancer of the University Health Shreveport, a clinical partner of the Health School of Medicine LSU Shreveport.

first clinical molecular profiling program in the region will use Caris' leading service industry overall profiling of the tumor molecular Caris Intelligence , to enhance the expertise clinical and research Feist-Weiller Cancer Center. It will expand the approach to personalized medicine clinic and provide a more precise treatment plan for patients. The partnership with Caris also includes clinical support, and patient education and physician integration system. It also creates a forum to pursue joint research opportunities.

"As the only institution within 250-mile offer these capabilities, our partnership with Caris is essential to provide specific, personalized care for cancer patients in our center every year," said Glenn Mills, MD FACP, Professor and Director of Feist-Weiller Cancer Center. "this type of technology is integral to better understand the unique molecular features of the disease of a patient, allowing a more targeted treatment planning . "

Cherie-Ann O. Nathan, MD, FACS, Chair and Professor, Director of Head and Neck Oncology and Surgical Research, believes that molecular profiling program will not only raise the level of clinical care for patients, but also of the Center research programs.

"Organ preservation using radiation therapy with or without chemotherapy is often used as an alternative to surgery for the disease at an advanced stage. However, radiation resistance in the head and neck often results in the lack of response to treatment, "said Dr. Nathan." Feist-Weiller Cancer Center is the first to Molecularly resistant genes with radiation profile for Caris identify potential patients who can not benefit from radiation treatment or benefit from alternative radiosensitizing chemotherapy. "

in recent years, molecular profiling has become a valuable tool for oncologists to take treatment decisions for patients with difficult treatment and / or rare and aggressive cancers. Caris molecular Intelligence correlates molecular data of a tumor with biomarker associations / drug the last clinical and scientific literature on cancer. This information is used to recommend more or less likely to benefit the patient treatment. It will also identify potential clinical trials to the patient. The system utilizes analysis of traditional pathology methods, and more recently developed DNA sequencing technologies.

"Every day oncologists in making critical decisions about clinical care that require the most accurate, reliable and feasible, based on each single tumor patients," said David D. Halbert, Chairman -Director General of Caris Life Sciences. "As a leader in the profiling of the complete tumor for cancer, we are pleased to work with Feist-Weiller Cancer Center at LSU and their experts to create a molecular profiling program that will offer these advanced process information - information which may help patients better control their disease. "

A new study fMRI aims to develop efficient real-time method for detecting the activation of the brain in AD patients

Tags
A new study fMRI aims to develop efficient real-time method for detecting the activation of the brain in AD patients -

Researchers at the University Hospitals Case Medical Center begin a functional magnetic resonance imaging study (fMRI) for detecting how the brain activation in patients at an early stage and intermediate of Alzheimer's disease compared to those without it.

When a part of the brain is activated by a task, the blood flows in this part of the brain. "FMRI is used to analyze brain activation patterns revealed through blood flow patterns that occur after administration of a stimulus, like showing someone a picture," said Curtis Tatsuoka, PhD , lead researcher of a new study which hopes to develop a faster, more accurate method in real time and more efficient for fMRI experiment. This is an important tool to study how the disease impacts brain function in Alzheimer's.

with the support of Philips healthcare, Dr. Tatsuoka and Alan Lerner, MD, director of the Center for brain health and memory at UH Case Medical Center, will study brain activation in using fMRI while participants perform research tasks such as solving math problems or remember names associated with people's faces.

"We expect that people with Alzheimer's disease have less brain activation, and less blood flowing to portions of their brains during the tasks compared to people without Alzheimer's disease to do the same tasks, "said said Dr. Lerner, who is co-principal investigator of the study and professor of neurology at the medical faculty of Case Western Reserve University. "We can use the images of blood flow as a measure of brain health or severity of the disease."

Dr. Tatsuoka, a biostatistician at the Department of Neurology at UH Case Medical Center and Case Western Reserve University School of Medicine, said the detection of blood flow changes in fMRIs can be difficult because they can be hidden by many extraneous information, or "noise" in the image. To compensate for the noise, researchers have patients repeat tasks again and again for a predetermined number of times while undergoing imaging.

"It may take a lot of experimentation to detect the signal," said Dr. Tatsuoka. "You ask patients to repeat over and over a task, and you could get the same results every time, but after a while, they could also become tired or simply move their heads too often, which makes the flow models blood difficult to determine. "

" We hope to develop new experiences that can be analyzed in real time while the experiments are in progress and may change based on the responses of an individual. ideally, they would be shorter and more accurate experiments, "said Dr. Tatsuoka. "We do not want to understand someone test, and we do not want more testing someone."

With the help of the Philips engineers, it will test statistical models that can proactively detect changes in blood flow in the research participants. He predicts that the real-time analysis of the fMRI data will reduce brain scan time to 50 to 60 percent in healthy participants.

They also seek ways of measuring cognitive reserve. Cognitive reserve refers to the ability of the neuronal brain efficiency in activation while performing tasks, and ability to compensate for neuronal damage. Thus is related to the strength of brain disease. cognitive reserve can vary significantly between AD patients. "Some patients can have significant neuronal damage, while maintaining cognitive abilities, and it is interesting to see how it arises," said Dr. Tatsuoka.

"This pilot study has the potential to provide a way to quantify cognitive reserve and potentially provide neurologists with an additional tool to evaluate the stage of cognitive impairment, "said Dr. Lerner." Although there is no cure for Alzheimer ' Alzheimer, better and earlier diagnosis can help improve the quality of life of a patient. "

the UH study will include early stage research topics of Alzheimer's disease (AD) those with cognitive impairment mild, and healthy patients of the same age. Currently, Drs. Tatsuoka and Lerner and Philips engineers are running tests on MRI in the preparation of the study.

Wednesday, November 23, 2016

Partial nephrectomy offers nearly equivalent lengths of fight against cancer compared to radical nephrectomy

Tags
Partial nephrectomy offers nearly equivalent lengths of fight against cancer compared to radical nephrectomy -

tumor destruction procedures guided needle offer nearly equivalent lengths of local control cancer compared to surgery for patients with small tumors of kidney cancer, according to results of a large study published in the journal European Urology. "If validated, these data suggest that an update clinical guidelines would be justified," says lead study author, R. Houston Thompson, M.D., a urologist at the Mayo Clinic.

Dr. Thompson said radical nephrectomy - surgical removal of the entire kidney - has always been the standard of care for the management of kidney cancer; However, partial nephrectomy - surgical removal of tumors of a kidney while sparing healthy tissue -Has become more and more common because of its advantages nephron savings and similar fight against cancer. The nephron is the part of the kidney that filter toxins from the blood.

"We undertook this study because direct comparisons of results in patients with kidney cancer who received partial nephrectomy (PN), radiofrequency ablation (RFA) - Destruction of the tumor using intense heat and cryoablation - destruction of the tumor using extreme cold. - lacking, especially institutions that regularly perform all three of these procedures, "says Dr. Thompson

the researchers studied a total of 1,803 patients. among patients with tumors 4 cm or less, 1,057 patients received PN, 180 received RFA and 187 received cryoablation. recurrence-free survival was similar between the three treatment groups while metastasis-free survival was significantly better for patients who received PN and cryoablation compared to patients treated with RFA. for 379 patients with tumors 4-7 cm, length of recurrence-free survival without metastases were Similar between PN and cryoablation. In this group, 326 underwent PN and 53 received cryoablation.

"cryoablation and RFA have traditionally been thought to provide inferior results compared to surgical removal. Our findings of nearly equal success, if correct, should encourage further research on these treatment modalities in patients with kidney cancer in early stage, "says Dr. Thompson.

Researchers identify important therapeutic target for lung cancer-small cell

Tags
Researchers identify important therapeutic target for lung cancer-small cell -

UT Southwestern Medical Center have identified a protein called ASCL1 which is essential for the development of lung cancer small cell and that, when they are deleted in the lungs of mice, prevents cancer from forming.

new results identify ASCL1 as an important therapeutic target for cell lung cancer, for which there has been little change in the treatment of the past 30 years.

"We used a transgenic mouse model that develops a human cell lung cancer and identified as two regulatory pathways which in turn vulnerabilities in this cancer, revealed," said the author principal, Dr. Jane E. Johnson, professor of neuroscience and pharmacology and a member of Harold C. Simmons Comprehensive cancer Center at UT Southwestern.

The results, published in the Journal Cell reports are important because the survival of patients with cell lung cancer is poor and few therapies are available.

"lung cancer small is a devastating disease which is diagnosed in 30,000 people per year in the United States and represents about 15 percent of cases of lung cancer. Most patients survive one year or less and therapy has not changed significantly in 30 years. Our work shows the possibility of developing entirely new types of targeted therapies for cell lung cancer by focusing on ASCL1 "said Dr. John D. Minna, professor and director of the Hamon Center for Therapeutic Oncology Research and director of the WA "Tex" and Deborah Moncrief Jr. Center for cancer Genetics. He is a professor of internal medicine and pharmacology, co-director of the Experimental Therapeutics of cancer Program Simmons cancer Center and Distinguished Chair holder Max L. Thomas in Molecular oncology lung, and Sarah M. and Charles E. Seay Distinguished Chair in cancer research.

Signs and symptoms of lung cancer cell include coughing, shortness of breath and chest pain, and rapid development of widespread disease around the body. patient smoking is the main risk factor for lung cancer small cell, according to the National Cancer Institute, which helped fund the study and prevention of cancer and the Texas Research Institute.

the research team, which included Dr. Melanie H. Cobb, acting director of the Simmons Cancer Center and professor of pharmacology, has determined that the ASCL1 protein found in most small tumors of cancer small cell lung is necessary for the formation of the disease. When the researchers deleted ASCL1 in the lungs of mice genetically engineered to develop lung cancer small cell loss prevented the development of cancer.

In addition, the researchers were able to distinguish between the tumor-promoting function ASCL1 and related proteins, NEUROD1 in lung cancer small cell. Some small cancers ASCL1 expressed cell lung while others expressed NEUROD1, and although both genes regulate different processes in cells, the two seem to control the genes that are important in the conduct of this cancer.

Dr. Johnson, holder of the Chair Distinguished Shirley and William S. McIntyre neuroscience, studied the roles of ASCL1 in the developing nervous system for many years, and was able to identify new roles for the protein in lung cancer small cell using UT Southwestern 'sGenomics and basic microarray facility that provides molecular advanced technologies and services to hundreds of researchers pursuing different research projects.

Tuesday, November 22, 2016

Study finds unexpected process for the acquisition of drug resistance in cancers of the breast

Tags
Study finds unexpected process for the acquisition of drug resistance in cancers of the breast -

A laboratory study revealed a totally unexpected process for the acquisition of drug resistance that bypasses the need to restore DNA damage repair in breast cancer who have BRCA1 or BRCA2 mutants. The results, reported by André Nussenzweig, Ph.D., and Shyam Sharan, Ph.D., at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, appeared July 21 , 2016, in Nature .

In normal cells, BRCA1 and BRCA2 proteins act as DNA damage sensors, surveyors, and stakeholders. They help to perform complex functions that facilitate the repair of damaged DNA. People who inherit certain mutations in either the BRCA1 or BRCA2 gene have defective DNA repair and increased risk of breast cancer developing, ovarian and other cancers. In particular, mutations in the BRCA1 and BRCA2 genes account for 20 percent to 25 percent of hereditary breast and 5 percent to 10 percent of all breast cancers. The decrease in the ability to repair breaks in DNA in cells with a BRCA1 or BRCA2 mutation renders the cells sensitive to DNA damaging drugs. However, breast cancer eventually develop resistance to these drugs. A documented mechanism for the development of drug resistance in these tumors is by restoring specify the DNA repair pathways that repair DNA breaks caused by chemotherapy.

The Nussenzweig lab has spent the last decade trying to understand the cellular mechanisms that regulate DNA repair in normal and disease states. "These are complex mechanisms that tumor cells evolve to circumvent the need for repair of specific DNA that form the basis of our study," said Nussenzweig. "A deeper understanding of the processes that lead to drug resistance in BRCA1 / 2-mutated tumors will lead to new therapeutic approaches that target specific vulnerabilities of the tumor."

In this study, researchers linked to the protection and stabilization of DNA replication forks as a major contributory mechanism for drug resistance in breast and ovarian / 2 -mutants BRCA1. Replication is a cellular process that produces two DNA copies indistinguishable from a single DNA molecule. This DNA-copying process is an essential step in cell division and occurs at defined locations called replication forks.

The movement of a replication fork as it migrates along a DNA molecule can be disturbed by the presence of a diverse group of DNA structures and proteins, collectively and loosely called replication barriers fork. This disruption results fork Replication migration in what is called a fork stalled. When replication fork stalling, the BRCA1 and BRCA2 proteins are called to protect the newly synthesized DNA strands. If these proteins are absent, the replication fork is destabilized and the newly synthesized DNA is degraded, which increases genomic instability and increases susceptibility to DNA damaging drugs.

The investigators were able to identify other proteins, such as PICTs, CHD4 and PARP1, actively promote the replication fork destabilization by recruiting enzymes that degrade the newly synthesized DNA. The absence of these proteins protected the DNA at replication forks and remarkably reversed the drug sensitivity of both BRCA1 and BRCA2 mutant cells, which makes the drug resistance. These studies also highlighted the complex ways in which tumor cells can escape chemotherapeutic interventions and develop resistance to drugs because disrupting the activity of several proteins directed to the same point of the protection of replication forks the end. These findings are particularly relevant in the clinical setting, where the expression of these proteins appears to be an indicator of how patients with BRCA1 and BRCA2-mutant cancers respond to chemotherapy treatment with DNA damaging agents.

Together, these results highlight the importance of the obstacles replication fork to genomic instability and sensitivity to medication in the context of BRCA1 / 2 The results also suggest that cellular levels these proteins could be used as a prognostic factor of acquired resistance in cancers / 2 BRCA1-mutant.

"Our work starts not only narrow, but also redefine the current dogma in the field, which stipulates that the restoration of DNA repair pathways are the only means by which BRCA1 / 2 mutant cells can become drug resistance, "said Nussenzweig.

AEG-1 protein blocks the effects of retinoic acid in the leukemia and liver cancer

Tags
AEG-1 protein blocks the effects of retinoic acid in the leukemia and liver cancer -

Retinoic acid is a form of vitamin A that is used to treat and help prevent the recurrence of a variety of cancers, but for some patients, the drug is ineffective. The reason for this resistance was uncertain until this week when researchers from Virginia Commonwealth University (VCU) Massey Cancer Center have shown that a protein called AEG-1 blocks the effects of retinoic acid on leukemia and liver cancer. Because AEG-1 is overexpressed in most cancers, these findings could impact the care of countless cancer patients.

Study details were published this week in the online edition of the journal Cancer Research , a journal of the American Association for Cancer Research. The team of scientists led by Devanand Sarkar, M.B.B.S., Ph.D., has shown that AEG-1 protein binds to retinoid X receptors (RXR), which help regulate cell growth and development. RXR is usually activated by retinoic acid, but overexpressed AEG-1 protein in cancer cells block these signals and help promote tumor growth. Using complex animal models, researchers have shown that blocking the production of AEG-1 has retinoic acid for deeply kill cancerous liver cells.

"Our results are the first to show that AEG-1 interacts with the retinoid X receptor," said Sarkar, Harrison Scholar at VCU Massey Cancer Center, Blick Scholar and Associate Professor in Human and Molecular Genetics Department member of the VCU Institute of molecular medicine (VIMM) at VCU School of medicine. "This research has immediate clinical relevance such as doctors could start patients screening for cancer AEG-1 expression levels in order to whether retinoic acid should be prescribed. "

Sarkar and his colleagues studied AEG-1 for years. They were the first to create a mouse model demonstrating the role of AEG-1 in liver cancer, and they have been actively working to develop targeted therapies that block AEG-1 production. This study expanded their knowledge of the molecular interactions of AEG-1.

"We continue to test combination therapies involving AEG-1 and inhibition of retinoic acid in animal models, and early results are promising," said Sarkar. "If we continue to see these results in more complex experiences, we hope to eventually propose a phase 1 clinical trial in patients with liver cancer. "

Monday, November 21, 2016

UH Case Medical Center offers a new treatment approved by the FDA for obstructive sleep apnea

Tags
UH Case Medical Center offers a new treatment approved by the FDA for obstructive sleep apnea -

University Hospitals (UH) Case Medical Center is the first in Ohio and among the first in the UK to begin offering a new treatment approved by the FDA for obstructive sleep apnea (OSA).

This first of its kind treatment consists of a small implantable system called Inspire ™ Upper Airway Stimulation (UAS) therapy. It has been clinically proven to significantly reduce apnea events of sleep and improve the quality of life for people who can not tolerate continuous positive airway pressure (CPAP).

UH Case Medical Center was one of the clinical trial sites for stimulation therapy for the reduction Apnea (the STAR Trial) study, and the results were published in New England Journal of Medicine (9 January 2014). The results of the STAR trial showed that Inspire therapy reduces apnea events by 68 percent and significantly improved key quality of life measures.

Over 18 million Americans suffer from obstructive sleep apnea (OSA), which is characterized by repeated episodes of collapse of the upper airway during sleep. Patients with OSA stop breathing frequently during sleep, often for a minute or more. "Sleep apnea is as common as adult diabetes and asthma and consequences of OSA range disrupt life in danger," said Kingman Strohl, MD, who was the principal investigator of the study UH and co-author of the NEJM article. "While many patients have found help with CPAP, for some patients, it is too difficult to use, and therefore ineffective."

Inspire meaning of respiratory therapy and provides a slight stimulation of key respiratory muscles, which keeps the airway open during sleep. Using a handheld programmer, patients can control when the Inspire therapy is enabled or disabled. Unlike other surgical procedures to treat sleep apnea, Inspire therapy does not require removing or permanently change the anatomy of the face and respiratory tract of a patient.

"Inspire therapy is an important addition to the options we can offer to patients with obstructive sleep apnea," said Diana Ponsky, MD, an otolaryngologist who will be one of the ear surgeons , nose, throat and system implementation at UH. "Untreated moderate to severe OSA puts patients at increased risk of cardiovascular disease, accidents and death. Inspire therapy provides us with an effective new treatment for use in a select group of our CPAP intolerant patient population. "

Sunday, November 20, 2016

New combination treatment improves overall survival in patients with malignant melanoma

Tags
New combination treatment improves overall survival in patients with malignant melanoma -

Bottom Line: Among patients with melanoma, those who received both ipilimumab (Yervoy) and treatment local devices such as radiation therapy or ECT had a significantly prolonged overall survival compared to those who received only ipilimumab, according to a retrospective clinical study

Journal in which the study was published :. Cancer Immunology Research , a journal of the American Association for Cancer Research

Author :. Theurich Sebastian, MD, professor and medical researcher at Integrated Oncology Centre (IOC) at the University Hospital of Cologne, Germany

Background :. ipilimumab is an immunotherapy that has revolutionized the treatment of malignant melanoma, a very aggressive type of skin cancer, according Theurich. About 20 percent of patients receiving ipilimumab achieve lasting responses, which is a major advance compared with historical results, but doctors-scientists are looking for ways to increase the percentage of patients that take a long-term benefit of this immunotherapy, he added.

Currently, local treatment devices are not used to try to cure patients with malignant melanoma; rather, they are used to relieve the symptoms caused by melanoma tumors, explained Theurich

How the study was conducted and the results :. Theurich and colleagues analyzed data from 127 patients with malignant melanoma who were treated consecutively at four cancer centers in Germany and Switzerland. Eighty-two patients received ipilimumab alone and 45 received ipilimumab and the local device treatment to relieve symptoms associated with the tumor.

The median overall survival for patients receiving ipilimumab and the local device treatment was 93 weeks against 42 weeks for those receiving. only ipilimumab

After excluding patients with brain metastases from the analysis because these patients are not evenly distributed between the two treatment groups, the median overall survival benefit for those receiving ipilimumab and local peripheral treatment remained - 117 weeks compared to 46 weeks for those receiving ipilimumab only

Author Comment :. "We found that adding local devices treatments, including external beam radiation therapy, ECT, or internal radiation therapy, systemic therapy ipilimumab doubled the chances of survival in our cohort of patients and did not increased side effects related to immunity, "said Theurich. "Importantly, this survival advantage seemed overcome even traditional risk factors for poor outcomes. This suggests that this combination could be an option for all patients with malignant melanoma, which is currently being tested in prospective clinical trials underway.

"Our results are consistent with those previously reported for 29 patients in the US with ipilimumab and local radiotherapy," continued Theurich. "Having data from different parts of the world enhances the validity of the results, especially if you are dealing with retrospective analyzes. In addition, all patients were treated with the same dose of ipilimumab, while those of the previous study received doses ranging because they have been treated in a clinical trial with dose escalation.

"We have also been able to begin studying the potential immunological mechanism underlying the benefit of adding a local device ipilimumab treatment," added Theurich. "It seems that the local treatment devices activate immune cells, which are then able to attack tumors at sites outside the local treatment site, however, we study this new in prospective studies.".

limitations: According Theurich, the main limitations of the study are that data are collected prospectively and randomly, but the validity of the results is being tested in prospective clinical trials.

University of Kansas researcher wins grant to study the role of dietary supplement in muscle growth

Tags
University of Kansas researcher wins grant to study the role of dietary supplement in muscle growth -

A Kansas University professor has been chosen to take part in a grant project which will test the role of a food supplement in muscle growth for everyone from athletes to seniors and also was named educator of the year by the funding agency.

Andrew Fry, professor of health, sport and exercise science, will have a co-investigator on a grant from the National Strength and Conditioning Association which investigates the role of nitric oxide synthase, a compound which stimulates the production of nitric oxide, which appears to play a role in hypertrophy, or muscle growth.

"It certainly has the potential for high-level artists like athletes," Fry said the compound. "But it also has implications for a number of people who need to grow muscle for a variety of reasons, such as the elderly, patients struggling against cancer and many others."

Fry proceed to trial with colleagues Zsolt Radak and Zsolt Murlasits, the faculty of the Semmelweis University in Budapest, Hungary. The researchers will test the compound in rats. Rats have three major muscles of interest in their legs, one primary and two "support" muscles. support the muscles will be removed in a group of rats. Some will give the compound as a supplement to their food and other receive a placebo. The rats will take part in a program designed to mimic the strength conditioning. The remaining muscle will certainly make up for the other two, Fry said, but researchers will see what role the supplement in that muscle growth by examining the signaling pathways and the role of a protein known as mTOR name .

"the goal is to see if a food supplement with nitric oxide synthase has an effect. We will look at the size of individual muscle fibers and we will look for specific proteins that are activated when the muscle growth occurs, "Fry said.

The results could potentially make a difference in both sports science and exercise. the two are often confused because of their similarities. When sport science focuses mainly on improving performance on the playing field, exercise science focuses on improving health , force and associated factors in people for purposes such as physical therapy, general fitness, personal training, military, and law enforcement and recovery of the disease.

Fry will travel Budapest regularly for research. in addition to the grant proposal, it intends to help establish contacts for students and lay the foundation for exchanges between the two universities. This network could lead to research opportunities for students, greater collaboration between faculty members in the two countries and an opportunity for students from each country to study abroad.

Fry's work with students recently earned him the title of "Educator of the Year" by the National Strength and Conditioning Association. He was nominated for the award and selected based on their work in the classroom, teaching philosophy, community service and student outcomes, such as internships. Fry teaches courses in methods of strength training and conditioning, kinesiology, biomechanics, physiology of skeletal muscle and exercise endocrinology. He also volunteered with sports organizations field of youth and recently wrote the "Workbook Training Force." The book guides students through the process of decision theories they learn in their classes and use them to design a comprehensive strength and conditioning program for a variety of public and explain how and why they designed the program as they did.

"(the book) looks at how you can create a customized detailed program to meet the needs of an individual or an organization, "said Fry. "Whether the goal is rehabilitation, general fitness, sports, a school setting or others, students are required to explain why they chose what they did. From an educational point of view, it is easy to talk about, now you have to go do and be responsible. "

Saturday, November 19, 2016

CD157 important in malignant pleural mesothelioma

Tags
CD157 important in malignant pleural mesothelioma -

By Laura Cowen, medwireNews Reporter

CD157 plays a key role in the progression of malignant pleural mesothelioma (MPM) and may be useful in stratifying patients into different prognostic groups, the Italian research suggests.

CD157 is known to contribute to tumor progression in ovarian cancer by promoting mesenchymal parallel differentiation between ovarian cancer and mesothelial indicate that CD157 may also be involved in MPM, explained Ada Funaro ( Turin University) and colleagues.

To test this hypothesis, Funaro and team conducted in vitro and in vivo using human cell lines MPM and MPM samples of surgical tissue.

using the reaction in reverse transcriptase polymerase chain and flow cytometry, they detected CD157 mRNA and protein expression in two of five epithelioid cell lines and MPM in one of the three cell lines biphasic MPM.

Expression was also detected by immunohistochemistry in 85.2% of 81 MPM samples of surgical tissues and was evenly distributed between epithelioid (86.5%) and biphasic (84.0%) tumors.

The statistical analysis revealed that CD157 expression was not correlated with sex, patient age at surgery, histology, history of asbestos, stage of the disease or the prognosis of patients when the MPM 81 surgical samples were stratified by the median CD157 histology (H) -Score 50.

Similarly, when the data were analyzed according histotype, it there was no correlation between survival and CD157 H-score in patients of epithelioid tumors.

However, the reverse was true for biphasic MPM, where a high CD157 H-score (> 50) was significantly associated with worse survival compared to a low score, a median of 13.1 against 20.4 months, and a hazard ratio of 2.43.

This finding has prompted researchers to further investigate the influence of CD157 on the behavior of tumor cells in vitro.

They report that, in cell lines biphasic MPM, knockdown of CD157 in CD157 positive cells significantly reduced cell growth, motility and invasiveness, whereas forced expression of CD157 in cell negative CD157 strengthened each of these variables. In contrast, no effect was observed in the lines of epithelioid cells.

In addition, increased expression of CD157 in cell lines BPM biphasic correlated with increased resistance to platinum-based chemotherapy, by the activation of the mTOR pathway, which is a known contributor to mesothelioma progression.

and patients with biphasic MPM and an expression of high CD157 receiving postoperative platinum based chemotherapy showed a trend towards reduced survival compared to those with low expression of CD157 which received the same type of treatment.

"These data suggest that CD157 may be a promising candidate as a predictive marker of response to platinum-based therapy in MPM biphasic patients," Funaro and co-authors conclude in Oncotarget .

medwireNews licensed by permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.

Researchers discover oldest evidence of cancer in 1.7 million years old fossil

Tags
Researchers discover oldest evidence of cancer in 1.7 million years old fossil -

An international team of researchers led by scientists at the University of Evolutionary Studies Institute of the Witwatersrand and the South African Centre for excellence in PalaeoSciences announced today in two papers, published in the South African Journal of science , the discovery of the earliest evidence for tumors bone cancer and further described in the human fossil record.

dated the discovery of a foot bone ago about 1.7 million years the Swartkrans site with definitive evidence of malignant cancer, grows the oldest date of the return of these disease lately in the deep prehistory. Although the exact species that the foot bone belongs is unknown, it is clearly that of a hominid, or bipedal by human relationship.

In an accompanying paper appearing in the same journal, a team of scientists working to identify tumor oldest ever found in the human fossil record, a benign tumor found in the vertebrae of the well known Australopithecus sediba child, Karabo from the site of Malapa, and dated back almost two million years of age. The oldest hominid previously demonstrated as possible tumor was found in the rib of a Neanderthal and dated about 0,000 years old.

Edward Odes, a Wits doctoral candidates and senior author of the Cancer paper, and co-author on the paper of the tumor, note "modern medicine tends to assume that cancers and tumors in humans are diseases caused by lifestyle and modern environments. our studies show the origin of these diseases occurred in our ancestors millions of parents years before modern industrial societies existed. "

The cancer in a bone of the foot, a metatarsal, has been identified as osteosarcoma, an aggressive form of cancer that usually affects younger people in modern humans, and, if untreated usually leads to death early. "Due to its preservation, we do not know if the only cancerous foot bones belong to an adult or a child, or if the cancer has caused the death of this person, but we can say this would affect the ability of people walk or run, "said Dr. Bernhard Zipfel, a scientist at Wits and an expert on the foot and the locomotion of early human parents. "In short, it would have been painful."

The lead author of the tumor paper and co-author of the study of cancer, Dr. Patrick Randolph-Quinney Wits University and the University of Central Lancashire in the UK, suggests "the presence of a benign tumor in Australopithecus sediba is fascinating not only because it is in the back, an extremely rare place for such a disease manifest in modern humans, but also because " it is in a child. This, in fact, is the first evidence of such a disease in a young individual in the entire human fossil record. "

Prof. Lee Berger, author of the two documents and leader Malapa project where fossil vertebra was found adds, "not only has there been an assumption that these kinds of cancers and tumors are diseases of modernity, these fossils demonstrate clearly that they are not, but we as modern human beings expose as a consequence of living longer, but this rare tumor is located in a young child. The history of these types of tumors and cancers is much more complex than previously thought. "

two incidences of the disease were diagnosed using state of the art imaging technologies including those of the European synchrotron Research facility in Grenoble, France, CT medical Charlotte Maxeke hospital in Johannesburg, and micro-CT facility at the nuclear energy Corporation of South Africa Pelindaba.

"researchers in South Africa are at the forefront of the use of various methods X-Ray to discover new and interesting facts about ancient human relatives," notes Dr. Jacqueline Smilg, a radiologist based at Charlotte Maxeke hospital, who is the author of two papers and was involved in clinical diagnostics. "This is another good example of how modern science and clinical science of paleoanthropology working together in South Africa and with international collaborators to advance our understanding of diseases in both the past and present."

Friday, November 18, 2016

Pre-op PET / CT predicted stage I NSCLC benefit of adjuvant chemotherapy

Tags
Pre-op PET / CT predicted stage I NSCLC benefit of adjuvant chemotherapy -

By Lynda Williams, Senior medwireNews Reporter

preoperative imaging could help guide the use of postoperative adjuvant chemotherapy in patients with cancer of the early non-small cell lung (NSCLC), Japanese researchers believe.

Morihito Okada and colleagues from the University of Hiroshima, examined whether 18F-fluorodeoxyglucose positron emission tomography / computed tomography (FDG-PET / CT) results were significantly associated with outcomes of patients with stage T1b-2a NSCLC who were free node and metastatic disease.

The study included 174 patients with completely resected tumors, 0 received tegafur-uracil or adjuvant platinum-based chemotherapy and 84 did not.

Patients given adjuvant chemotherapy were significantly more likely than controls to achieve an interval without recurrence at 3 years (RFI, 0.6 vs 74.8%) and overall survival (OS 95.4 vs. 84.0%) than those who are not, the team reports in the Annals of Thoracic Surgery .

multivariate analysis, preoperative FDG-PET / CT normalized maximal absorption value (SUV max) of 2.6 or more predicted RFI significantly (relative risk [HR] = 8.03), while size greater than 30 mm tumor, pleural, vascular or lymphatic invasion were not significantly associated with RFI.

further analysis revealed that in patients with a maximum SUV of 2.6, those given adjuvant chemotherapy were significantly more likely than controls to achieve 3 years (RFI 82.8 vs 44.8%) and OS (93.0 vs 68.6%).

However, for patients with SUV max less than 2.6, adjuvant chemotherapy was not associated with significantly better survival.

The researchers suggest that the tumor size was not a significant predictor of results in their study because only participants with tumors with a diameter of 2 cm to 5 cm were enrolled.

In addition, FDG is associated with tumor growth in lung cancer, they said.

"We suggest not only the size of the tumor, but also the nature of the tumor defined by FDG-PET imaging / CT could predict the effectiveness of adjuvant chemotherapy," write Okada et al

They conclude :. "patients who are likely to derive greater benefit from adjuvant chemotherapy may be differentiated using SUV max together with the staging and the condition T" .

medwireNews licensed by permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.

MIT researchers develop portable device for the manufacture of biopharmaceuticals on request

Tags
MIT researchers develop portable device for the manufacture of biopharmaceuticals on request -

For doctors on the battlefield and doctors in remote areas or parts of the developing world, get quick access to needed drugs to treat patients can be difficult.

biopharmaceuticals, which are used in a wide range of therapies, including vaccines and treatments for diabetes and cancer, are typically produced in large fermentation plants centralized. This means they must be transported to the processing site, which can be costly, lengthy and difficult to perform in areas with poor supply chains.

Now, a system of mobile products, designed for the manufacture of a range of biopharmaceuticals demand, has been developed by researchers at MIT, with funding from the Defense Advanced Agency Research Projects (DARPA).

in an article published in the journal Nature Communications , the researchers showed that the system can be used to produce a single dose of treatment from a compact containing a small droplet cells in a liquid.

in this way, the system could eventually be carried out on the battlefield and used to produce treatments to the point of care. It could also be used to make a vaccine to prevent an outbreak of the disease in a remote village, according to lead author Tim Lu, associate professor of biological engineering and electrical and computer engineering, synthetic biology and head of the group in lab search MIT electronics.

"Imagine that you were on Mars or in a remote desert without access to a full form, you can program the yeast to produce drugs to local demand," says Lu.

system is based on a programmable yeast strain Pichia pastoris, which can be induced to express two therapeutic proteins when exposed to a particular chemical trigger. researchers selected P. pastoris because it can achieve very high densities on simple carbon sources and inexpensive, and is able to express large quantities of protein.

"We have changed the yeast so that it could be more easily engineered and may include more than one therapeutic in its repertoire, "says Lu.

hormone When the researchers exposed the yeast modified to β-estradiol estrogen, the cells express recombinant human growth (rhGH). In contrast, when they exposed the cells with methanol, the yeast expressed interferon protein.

The cells are maintained in a table-top microbioreactor millimeter scale, containing a microfluidic chip, which was originally developed by Rajeev Ram, a professor of electrical engineering at MIT, and his team, and marketed by Kevin Lee - a graduate of MIT and co-author -. through a spin-off company

a liquid containing the desired chemical trigger is first introduced into the reactor, to mix with the cells

has within the reactor the mixture of cells and chemical is surrounded on three sides by a polycarbonate. on the fourth side is a soft silicone rubber membrane permeable to gas.

By pressurizing the gas above the membrane, researchers are able to gently massage the liquid droplet to ensure its contents are completely mixed.

"This ensures that one milliliter (liquid) is homogeneous, and that is important because the distribution of these small scales, where there is no turbulence, takes time surprisingly long, "said Ram, who was also a senior author of the paper.

Because the membrane is permeable to gas, it allows oxygen to circulate through the cells, while any dioxide carbon they produce can be easily extracted.

the device continuously monitors the conditions in the microfluidic chip, including oxygen levels, temperature and pH to ensure an optimal environment for cell growth. It also monitors the cell density.

If the yeast is required to produce a different protein, the liquid is simply rinsed through a filter, leaving the cells behind fresh liquid. containing a new chemical trigger can then be added to boost production of the next protein.

Although other research groups have attempted to build microbioreactors, they are not given the opportunity to retain the protein producing cells when flushing liquid are mixed with said Ram. "You want to keep the cells as they are your factory," he said. "But you also want to quickly change their chemical environment, in order to change the trigger for the production of proteins."

The researchers are studying the use of the system in combination therapies, in which multiple treatments, such as antibodies, are used together.

a combination of treatments in this way can be expensive if each requires its own production line, Lu said.

"But if you could design a single strain, or perhaps even a strain consortium that grow together to produce combinations of organic products or antibodies, that could be a very powerful way of production of these drugs at a reasonable cost, "he said.

Thursday, November 17, 2016

BD Announces 5.1% increase in revenue for the third fiscal quarter

Tags
BD Announces 5.1% increase in revenue for the third fiscal quarter -

BD (Becton, Dickinson and Company) (NYSE: BDX), a company global medical technology leading, today announced quarterly revenue of $ 2.157 billion for the third quarter ended June 30, 2014, an increase of 5.1 percent from the period a year earlier, or 4.6 percent on a foreign currency-neutral basis.

"We are pleased with our strong third quarter results, with each of our segments contributing to growth," said Vincent A. Forlenza, Chairman, CEO and President. "Our performance demonstrates that constant our strategy remains strong in this dynamic healthcare environment. "

Third quarter and nine months 2014 financial results of operations
reported earnings per diluted share from continuing operations for the third quarter were $ 1.65 compared to $ 1.47 for the period of the previous year, representing an increase of 12.2 percent. On a foreign currency-neutral basis, earnings per diluted share from continuing operations for the third quarter increased 10.9 percent. The current quarter results include a pretax charge in R & D of $ 9 million or $ 0.03 per diluted share from continuing operations for the programming of asset write-offs and bonds. The results of the prior year included a charge of $ 22 million, or $ 0.07 per share from continuing operations, associated with a settlement antitrust lawsuit. Excluding the impact of these items, adjusted diluted earnings per share from continuing operations were $ 1.68 compared to $ 1.54 for the period of the previous year. This represents an increase of 9.1 percent or 7.8 percent on a currency-neutral basis.

For the nine months ended June 30, 2014, diluted earnings per share from continuing operations were $ 4.47 compared to $ 4.21 in the period last year. This represents growth of 6.2 percent, or 10.0 percent on a currency-neutral basis. Excluding the current quarter charge for the R & D program completion and settlement charge antitrust class action in the district last year, and other factors detailed in the accompanying reconciliation of non-GAAP financial measures to GAAP, adjusted diluted earnings per share from continuing operations for the nine-month period ending June 30, 2014 were $ 4.57 compared to $ 4.28 for the period of the previous year. This represents an increase of 6.8 percent, or 10.5 percent on a currency-neutral basis. Excluding the first quarter differential impact of the excise tax on the medical device, which entered into force in January 2013 under the Affordable Care Act patient protection US, and adjusted diluted earnings per share from continuing were $ 4.62 compared to $ 4.28 for the period of the previous year. This represents growth of 7.9 percent, or 11.7 percent on a currency-neutral basis.

Segment Results
In the medical sector BD, revenues worldwide for the quarter were $ 01000000, representing an increase of 5.3 percent compared to the previous year, an increase of 4.7 percent on a foreign currency-neutral basis. The growth in segment revenues was primarily driven by strong sales in medical surgical systems. For the nine months ended June 30, 2014, BD Medical revenues increased 6.1 percent, or 6.4 percent on a currency-neutral basis.

In the BD Diagnostics segment, worldwide revenues for the quarter were $ 679 million, an increase of 3.7 percent both on a neutral basis and reported abroad compared the previous year. Strong growth in Preanalytical Systems unit were partially offset by continued weakness in health and cancer of women in the US for the nine months ended June 30, 2014, revenues BD Diagnostics rose 2, 0 percent, 3.0 percent on a currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were $ 277 million, representing an increase of 7.7 percent compared to the previous year, an increase of 6, 6 percent on a foreign currency-neutral basis. The segment's growth was driven by solid investment instruments and a favorable comparison with the previous year. For the nine months ended June 30, 2014, BD Biosciences revenues increased 7.1 percent, or 7.6 percent on a currency-neutral basis.

geographical Results
third quarter revenues of US $ 871 million for an increase of 2.8 percent over the period last year. Sales outside the US were $ 12800000, representing an increase of 6.7 percent compared to the previous year, an increase of 6.0 percent on a foreign neutral basis . International revenues reflect the continued strength of the market and sales of emerging security product design.

For the nine months ended June 30, 2014, revenues in the US were $ 2,546,000,000, representing an increase of 1.8 percent compared with the period last year. Sales outside the US were $ 3,698,000,000, representing an increase of 7.1 percent compared to the previous year, or 8.1 percent on a foreign currency-neutral basis.

year 2014 Outlook for
The Company reaffirms its revenue guidance range previously communicated currency neutral 4.5 to 5.0 percent. On a reported basis, the Company expects revenue growth of 4.0 to 4.5 percent. The Company also reaffirmed its previous guidance for diluted earnings per share from continuing operations for the full year is between $ 6.22 and $ 6.25 excluding the impact of the adjustments previously mentioned above. On a reported basis, earnings per share for the full year 2014 expected to be between $ 6.12 and $ 6.15. This represents growth of 7.0 to 7.5 percent over 2013 adjusted diluted earnings per share of $ 5.81. On a foreign currency-neutral basis, diluted adjusted earnings per share growth is expected to be between 10.5 percent to 10.0, 11.0 to 11.5 percent excluding the impact of additional tax on the medical device. The Company expects to complete the acquisition, subject to market conditions, of $ 450 million of its common shares for the year 2014.

Malfunction of molecular signaling system removes mature blood cells fighting against sepsis

Tags
Malfunction of molecular signaling system removes mature blood cells fighting against sepsis -

When the body encounters an infection, molecular signaling system ramps up system infection battle of the body to produce more white blood cells to attack invading bacteria. Now researchers have discovered that face a massive bacterial infection leading to sepsis, the same failure of the signaling system, damaging the body's ability to fight the invaders.

In addition to the removal of mature blood cells fighting against the infection, dysfunction of this signaling system causes permanent damage to the blood producing cells in the body - called hematopoietic stem cells - which are found in the marrow bone. The research, by scientists at the Medical School of the University of Indiana, was recently published in the journal Stem Cell Reports . http://www.cell.com/stem-cell-reports/fulltext/S2213-6711(16)30057-1

Sepsis is a life threatening inflammatory response by the body system which can lead to serious bacterial infections. It is a growing problem: The number of hospitalizations for sepsis more than doubled from 00 to 08, reaching more than 1.1 million, according to the Centers for Disease Control and Prevention. Patients with severe sepsis or septic shock has a death rate (deaths) of about 40% -60%, with seniors with the highest mortality rates. Newborns and pediatric patients with sepsis have a mortality rate of 9% -36%.

"Our goal is to know what are the causes of this failure of the bone marrow during severe infections, and find ways to prevent," said Nadia Carlesso, MD, Ph.D., professor of pediatrics and of medical and molecular genetics at the IU school of medicine.

most research has focused on understanding and managing the late consequences of sepsis while little is known about the changes that occur in the bone marrow at early stages of the response to bacterial infection, when the opportunity for effective treatment could be available. The group of Dr. Carlesso has pioneered the study of bone marrow responses during acute infection. laboratory models with severe sepsis his group discovered that producing blood stem cells fail to continuously generate mature neutrophils, which are fighting the most critical cell bacteria.

"In this research, we determined that in cases of severe infection and sepsis, a key mechanism in the response of the body to infection is broken. These results indicate potential new targets for immune protection during major infections, "said Dr. Carlesso.

IU researchers focused on a set of proteins called toll-like receptors, which function as sentinel on cell surfaces. When the receivers detect the presence of invading bacteria, they send signals to the body's immune response system. researchers IU looked receptors toll 4 (TLR4), which activates both signaling pathways that stimulate producing more neutrophils in their current infections but eliminate during severe infections.

in a laboratory sepsis model using mice, the researchers found that two abnormal effects activated receptors toll 4 during a serious infection - removal of neutrophil production and damage-producing stem cells from bone marrow blood -. are mediated by two different molecules downstream of TLR4

"this study is a good start, which provides a more precise map to follow, but more research is needed to better understand this process and develop better, necessary, treatment strategies for many sepsis, "said Dr. Carlesso.

Wednesday, November 16, 2016

Expressive writing can improve health outcomes for survivors of breast cancer Asian American

Tags
Expressive writing can improve health outcomes for survivors of breast cancer Asian American -

Write fears, emotions and benefits of a diagnostic cancer can improve health outcomes for Asia survivors -American breast cancer, according to a study by a researcher at the University of Houston (UH).

"the key to the development of an intervention by expressive writing is writing instruction. Otherwise, writing is like a facts and recording events newspaper. the journal writing can be therapeutic, but often we do not get empirical data to determine if it is effective or not, "said Qian Lu, assistant professor and director of the Culture and health research Centre at UH.

"In my study, I find benefits for the physical and psychological health in the long term when the research participants wrote about their deepest fears and the benefits of a breast cancer diagnosis' she said.

Lu and his colleagues published a study entitled "a pilot study of Expressive writing Intervention Among Chinese breast cancer survivors," in health Psychology . The goal of his research is to reduce the psychological burden in patients minority especially among breast cancer survivors.

"Cancer patients, as war veterans in Iraq may experience symptoms of post-traumatic stress. Many times when cancer patients are diagnosed, they face a lot of emotional trauma. There has a sense of loss, depression, anxiety going in the treatment and how they are going to face in the future, "said Lu." they have a lot of emotional events that will in their lives. "

in his research, Lu, found little attention to the psychological needs of Asian Americans surviving breast cancer. previous studies have largely focused on non-Hispanic whites samples, and found a need for research in this little studied population. Some of the challenges noted with this population felt stigmatized shame associated with cancer, cultural beliefs to bear the burden alone to avoid disturbing the harmony, elimination emotions, and a lack of training for mental health professionals with cultural and linguistic competence.

"We thought a very interesting way to help this problem. It is actually quite simple. It is to express emotions using writing," she said. "What is interesting is that it has been proved as a scientific paradigm."

According to Lu, previous research found that writing about emotionally difficult events for only 20 to 30 minutes at a time on three or four days increased immune function. The release offered writing has had a direct impact on the body's ability to withstand stress and fight infection and disease.

"I based my study Chinese breast cancer survivors on the paradigm of research Pennebaker, and we have conducted a series of studies to change the paradigm for Asian Americans" said Lu.

rather than go to the hospital, Lu worked with a community partner to recruit participants. Lu's research team asked the participants to conduct an assessment of standardized health and then they were asked to write 20 minutes each week for three weeks. Three sealed envelopes were sent simultaneously to the participants with each envelope containing different instructions for writing the corresponding week. Questionnaires assessing health outcomes were sent to the participants at three and six months after completion of paperwork. semi-structured telephone interviews were conducted after the 6-month follow-up.

"The results of the study suggest the participants perceived the writing task to be easy, revealed their emotions, and described their experiences in writing that they had not said before other. The participants indicated that they wrote what they thought and felt and perceived the appropriate and useful intervention, "said Lu.

Lu added that the health outcomes associated with the intervention of expressive writing includes a decrease in fatigue, intrusive thoughts, and reduce post-traumatic stress after three months. It also noted a decrease in fatigue, post-traumatic stress, and increasing benefit of life and positive affect after six months.

Lu notes this study contributes to the growing literature of expressive writing, illustrating the feasibility and potential benefits between Chinese survivors of breast cancer using a community participatory research approach and a mixed method design . The results of the operation show that the writing has been associated with long-term health benefits of monitoring and how to adapt and use the intervention of expressive writing for minorities.